Clinical Validation Hub
The DiaRem score is validated across RYGB, LSG, and LAGB procedures in white and Hispanic populations.
Ready for Assessment
Based on patient age, baseline HbA1c, and pharmacological burden.
Verified
Last Review: 2026-07-17
| Age < 40 years | 0 pts |
| Age 40–49 years | 1 pt |
| Age 50–59 years | 2 pts |
| Age ≥ 60 years | 3 pts |
| HbA1c < 6.5% | 0 pts |
| HbA1c 6.5%–6.9% | 2 pts |
| HbA1c 7.0%–8.9% | 4 pts |
| HbA1c ≥ 9.0% | 6 pts |
| No Insulin use | 0 pts |
| Insulin use | 10 pts |
| Other Diabetes meds (Non-insulin) | 0 pts |
| Sulfonylurea or Meglitinide use | 3 pts |
| Score 0–2 (Group 1) | 85–100% Remission |
| Score 3–7 (Group 2) | 64–74% Remission |
| Score 8–17 (Group 3) | 23–34% Remission |
| Score 18–22 (Group 4) | 2–7% Remission |
Still CD et al. • Lancet Diabetes Endocrinol.. 2014;2(1):38-45. Original derivation and validation study involving 690 patients.
Aron-Wisnewsky J et al. • Surg Obes Relat Dis.. 2014;Confirmed the score's utility in predicting remission at 1 and 5 years in diverse surgical populations.
Last Comprehensive Review: 2026-07-17
Clinical Context
We think this might be relevant to the clinical guidance for DiaRem Score — T2DM Remission Predictor.
Clinical Context
We think this might be relevant to the clinical guidance for DiaRem Score — T2DM Remission Predictor.
Clinical Context
We think this might be relevant to the clinical guidance for DiaRem Score — T2DM Remission Predictor.
